Compare Amylx Pharmaceuticals Inc (AMLX) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Redwire Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Redwire Corporation trades at $10.07 (market cap $2.43B). The key difference: Redwire Corporation is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| AMLX | RDW | |
|---|---|---|
Market Cap | $1.98B | $2.43B |
Sector | Health | Technology |
52-Week High | $18.70 | $25.90 |
52-Week Low | $7.64 | $5.06 |
Enterprise Value | $1.70B | $2.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
RDW trades at $10.18, down 2.77% today amid bearish technical signals despite bullish analyst sentiment. The stock shows weak fundamentals with a -80.9% net income margin and three consecutive quarterly EPS misses. Recent news highlights volatility driven by SpaceX's market impact and RDW's capital raising activities, though new defense contracts provide some optimism.
The outlook remains high-risk due to persistent losses and cash burn, but analyst consensus suggests 87% upside to the $19 price target. Key risks include dilution from fundraising and intense space sector competition, requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
